Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) (SOURCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00246194 |
|
Recruitment Status :
Completed
First Posted : October 31, 2005
Last Update Posted : April 4, 2014
|
Sponsor:
Janssen, LP
Information provided by (Responsible Party):
Janssen, LP
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.
| Condition or disease | Intervention/treatment |
|---|---|
| Schizophrenia | Drug: risperidone (RISPERDAL CONSTA) |
This is a 2-year, prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study), multi-center (at multiple sites), longitudinal (study that involves repeated observations of the same outcomes in the same people over long periods of time), observational study (study in which the investigators/ physicians observe the patients and measure their outcomes) in adults with schizophrenia (mental disorder characterized by a breakdown of thought processes and by poor emotional responsiveness). Physicians will determine the appropriate treatment for their patients, according to their usual practice. Patients starting treatment with long-acting risperidone injection (an antipsychotic medication) and meeting all the study criteria will be enrolled in the study. They will receive a dose of 25, 37.5 or 50 mg of risperidone every 2 weeks by intramuscular injection, and continue their treatment for schizophrenia according to usual care by their physicians. Patients will be asked questions at baseline and every three months for a period of two years to assess: efficacy of the medication, how well the patient is functioning, use of healthcare resources (eg, emergency room visits and hospitalizations) patient work status, quality of life and patient satisfaction with the medicine. Safety will be monitored throughout the study duration of 2 years.
| Study Type : | Observational |
| Actual Enrollment : | 532 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA) |
| Study Start Date : | September 2004 |
| Actual Primary Completion Date : | November 2007 |
| Actual Study Completion Date : | November 2007 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Schizophrenia
MedlinePlus related topics:
Schizophrenia
Drug Information available for:
Risperidone
| Group/Cohort | Intervention/treatment |
|---|---|
|
Patients with schizophrenia
Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
|
Drug: risperidone (RISPERDAL CONSTA)
Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
Other Name: RISPERDAL CONSTA |
Primary Outcome Measures :
- Change from baseline to 24 months in Clinical Global Impression of Severity (CGI-S) scores [ Time Frame: Baseline (Month 0) to 24 months ]The CGI-S is a 7-point scale ranging from 1 to 7 (normal, not at all ill to among the most severely ill patients), which measures disease severity in psychiatric patients. The scale is completed by physician.
- Clinical Global Impression of Change (CGI-C) scores during 24 months [ Time Frame: 24 months ]The CGI-C is a 7-point scale ranging from 1 to 7 (very much improved to very much worse), which is used to rate the change in the patient's illness compared to baseline. The scale assesses the patient's improvement over time. The scale is completed by physician.
- Change from baseline to 24 months in Global Assessment of Function (GAF) scores [ Time Frame: Baseline to 24 months ]GAF is completed by the physician. GAF is a single item rating of the patient's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness. Respondents are asked to rate the subject's lowest level of functioning in the last week. GAF scores range from 0 to 100. (0 = Inadequate information, 1 = Persistent danger of severely hurting self or others and 100 = Superior functioning in a wide range of activities).
- Change from baseline to 24 months in Personal and Social Performance (PSP) scores [ Time Frame: Baseline to 24 months ]The PSP Scale is completed by the physician. PSP is a rating of a patient's level of functioning during the past month in 4 areas: (a) socially useful activities (including work and study); (b) personal and social relationships; (c) self-care; and (d) disturbing and aggressive behaviors. Scores range from 1 to 100. (1= Lack of autonomy in basic functioning and 100 = Excellent functioning in all 4 main areas).
- Change from baseline to 24 months in Strauss-Carpenter Levels of Function (LOF) scores [ Time Frame: Baseline to 24 months ]The Strauss-Carpenter LOF is completed by the physician. It consists of 9 items that can be grouped into 4 subscales: symptoms (absence of symptoms and recent hospitalizations), social contacts (frequency and quality of social contacts), work (quantity and quality of useful work), and function (ability to meet basic needs, fullness of life, and overall level of function). Each item is rated on a scale of 0 (worst functioning) to 4 (best functioning).
Secondary Outcome Measures :
- Change from baseline to 24 months in Quality of Life Assessment: Medical Outcomes Survey Short Form (SF-36) scores [ Time Frame: Baseline to 24 months ]Patients completed the SF-36. The survey includes 36 items and evaluates health status in the past 4 weeks, in 8 different areas, which can be broadly summarized as physical health (physical functioning [PF], role-physical [RP], bodily pain [BP] and general health [GH]) and mental health (vitality [VT], social functioning [SF], role-emotional [RE], and mental health [MH]). In addition, the SF-36 evaluates health status in 2 broadly-defined areas, mental health and physical health. Higher scores represent better health status.
- Change from baseline to 24 months in patient satisfaction with antipsychotic medication [ Time Frame: Baseline to 24 months ]Patients are asked a single question to evaluate patient satisfaction with their current Anti psychotic medication. The question is, "The way I feel about my current antipsychotic is:" and used a 7-point response scale from 1 to 7 (extremely dissatisfied to extremely satisfy).
- Change from baseline to 24 months in healthcare resource utilization [ Time Frame: Baseline to 24 months ]Healthcare resource utilization including dates of hospitalizations (inpatient), emergency room (ER) visits, and outpatient visits, consultations with specialists and general practitioners. Relapse rates (from psychiatric hospitalizations, suicidal behavior or homicidal behavior) are also captured as resource utilization.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adult patients diagnosed with schizophrenia
Criteria
Inclusion Criteria:
- Patients had schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated) that met disease diagnostic criteria as defined in Diagnostic and Statistical Manual of Mental Disorders IV ([DSM-IV]
- Requiring new treatment with long-acting risperidone injectable
- Patients were cooperative, reliable, and able to complete all aspects of the protocol
Exclusion Criteria:
- Use of an investigational drug in the past 30 days
- At risk to self or others
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00246194
Locations
| United States, Maryland | |
| Rockville, Maryland, United States | |
Sponsors and Collaborators
Janssen, LP
Investigators
| Study Director: | Janssen, LP Clinical Trial | Janssen, LP |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Janssen, LP |
| ClinicalTrials.gov Identifier: | NCT00246194 History of Changes |
| Obsolete Identifiers: | NCT01571154 |
| Other Study ID Numbers: |
CR005035 RIS-OUT-173 ( Other Identifier: Janssen, LP ) RISSCH4001 ( Other Identifier: Janssen, LP ) |
| First Posted: | October 31, 2005 Key Record Dates |
| Last Update Posted: | April 4, 2014 |
| Last Verified: | April 2014 |
Keywords provided by Janssen, LP:
|
Schizophrenia Mental disorder DSM-IV RISPERDAL CONSTA Risperidone |
Long-acting risperidone Disorganized Catatonic Paranoid |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Risperidone Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |